Positron emission tomography (PET) is being increasingly used for the evaluation of patients with known or suspected cancer at all phases of the management process from diagnosis, through staging to follow-up after treatment. The role of PET in therapeutic monitoring is expanding rapidly due to its ability to provide earlier and more robust identification of non-responders than provided by conventional non-invasive imaging approaches. PET can thereby potentially provide important benefits to the individual patient by allowing an earlier change to alternative treatments that may be more efficacious or by avoiding the unnecessary toxicity related to ineffective therapy. As therapies become ever more expensive, this could also produce cost savings because of earlier termination of ineffective treatment. Conversely, PET may demonstrate important biological effects despite a lack of apparent morphological response and therefore prevent premature withdrawal of effective therapies. Globally, the vast majority of therapeutic monitoring studies use the glucose analogue, fluorine-18 fluorodeoxyglucose (FDG) but new tracers such as fluorine-18 fluorothymidine (FLT) also offer promise for this application. In this review, the potential benefits and limitations of FDG PET are discussed along with suggestions regarding the most practical methodologies for response evaluation using this modality.

Author

Rodney J Hicks

Contact Details

Corresponding address:
Rodney J Hicks,
The Centre for Molecular Imaging, The Peter MacCallum Cancer Centre,
12 Cathedral Place,
East Melbourne VIC 2002,
Australia

Reference

ICIS Cancer Imaging Volume 5 Issue 1
DOI: 10.1102/1470-7330.2005.0006

Date Posted

21 June 2005

Print PDF

Size

3.45 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	13 seconds
ADSL 512Kb/s (Broadband):	55 seconds
64 Kb/s (ISDN):	7 minutes 21 seconds
33.3 Kb/s (Typical Modem):	14 minutes 7 seconds

Screen PDF

Size

395.72 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	6 seconds
64 Kb/s (ISDN):	49 seconds
33.3 Kb/s (Typical Modem):	1 minute 35 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.